Predictors of Metformin Monotherapy Failure in Gestational Diabetes Mellitus

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2022 May 6

PMID 35521811

Authors

Vania Benido Silva

Liliana Fonseca

Maria Teresa Pereira

Joana Vilaverde

Clara Pinto

Fernando Pichel

Maria do Ceu Almeida

Jorge Dores

Affiliations

Soon will be listed here.

Abstract

Objective: Metformin has emerged as a safe and effective pharmacological alternative to insulin in gestational diabetes mellitus (GDM), being associated with lower maternal weight gain and hypoglycemia risk. Nevertheless, glycemic control is unaccomplished in a considerable proportion of women only treated with metformin. We aim to determine the metformin monotherapy failure rate in GDM and to identify predictors of its occurrence.

Design And Methods: This was a retrospective multicenter study including pregnant women with GDM patients who started metformin as a first-line pharmacological treatment (n = 2891). A comparative analysis of clinical and analytical data between the group of women treated with metformin monotherapy and those needing combined therapy with insulin was performed.

Results: In 685 (23.7%) women with GDM, combined therapy to achieve adequate glycemic control was required. Higher pregestational BMI (OR 1.039; CI 95% 1.008-1.071; P-value = 0.013), higher fasting plasma glucose (PG) levels in oral glucose tolerance test (OGTT) (OR 1.047; CI 95% 1.028-1.066; P-value <0.001) and an earlier gestational age (GA) at metformin introduction (0.839; CI 95% 0.796-0.885, P-value < 0.001) were independent predictive factors for metformin monotherapy failure. The best predictive cutoff values were a fasting PG in OGTT ≥87 mg/dL and GA at metformin introduction ≤29 weeks.

Conclusions: In 685 (23.7%) women, combined therapy with insulin to reach glycemic control was required. Higher pre-gestational BMI, fasting PG levels in OGTT ≥87 mg/dL and introduction of metformin ≤29 weeks of GA were independent predictive factors for metformin monotherapy failure. The early recognition of these characteristics can contribute to the establishment of individualized therapeutic strategies and attain better metabolic control during pregnancy.

References

Hartling L, Dryden D, Guthrie A, Muise M, Vandermeer B, Donovan L . Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med. 2013; 159(2):123-9. DOI: 10.7326/0003-4819-159-2-201307160-00661. View

Leite Ramos de Souza M, Ribeiro E Silva R, Silva T, de Oliveira L, Dienstmann G, do Nascimento I . Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus. Rev Bras Ginecol Obstet. 2019; 41(12):697-702. PMC: 10316792. DOI: 10.1055/s-0039-1700796. View

Tertti K, Ekblad U, Koskinen P, Vahlberg T, Ronnemaa T . Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab. 2012; 15(3):246-51. DOI: 10.1111/dom.12017. View

Kelley K, Carroll D, Meyer A . A review of current treatment strategies for gestational diabetes mellitus. Drugs Context. 2015; 4:212282. PMC: 4509429. DOI: 10.7573/dic.212282. View

Pollex E, Feig D, Koren G . Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer. J Matern Fetal Neonatal Med. 2010; 23(3):224-8. DOI: 10.3109/14767050903550881. View

Wang F, Han L, Hu D . Fasting insulin, insulin resistance and risk of hypertension in the general population: A meta-analysis. Clin Chim Acta. 2016; 464:57-63. DOI: 10.1016/j.cca.2016.11.009. View

Catalano P . The impact of gestational diabetes and maternal obesity on the mother and her offspring. J Dev Orig Health Dis. 2014; 1(4):208-15. PMC: 6691723. DOI: 10.1017/S2040174410000115. View

Dickens L, Thomas C . Updates in Gestational Diabetes Prevalence, Treatment, and Health Policy. Curr Diab Rep. 2019; 19(6):33. DOI: 10.1007/s11892-019-1147-0. View

Khin M, Gates S, Saravanan P . Predictors of metformin failure in gestational diabetes mellitus (GDM). Diabetes Metab Syndr. 2018; 12(3):405-410. DOI: 10.1016/j.dsx.2018.01.003. View

10.

McGrath R, Glastras S, Hocking S, Fulcher G . Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. Diabetes Res Clin Pract. 2016; 116:96-9. DOI: 10.1016/j.diabres.2016.04.051. View

11.

Metzger B, Gabbe S, Persson B, Buchanan T, Catalano P, Damm P . International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33(3):676-82. PMC: 2827530. DOI: 10.2337/dc09-1848. View

12.

. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S17-S38. DOI: 10.2337/dc22-S002. View

13.

Zhu Y, Zhang C . Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective. Curr Diab Rep. 2016; 16(1):7. PMC: 6675405. DOI: 10.1007/s11892-015-0699-x. View

14.

Moore L, Clokey D, Rappaport V, Curet L . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2009; 115(1):55-59. DOI: 10.1097/AOG.0b013e3181c52132. View

15.

Ashoush S, El-Said M, Fathi H, Abdelnaby M . Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus. J Obstet Gynaecol Res. 2016; 42(6):640-7. DOI: 10.1111/jog.12950. View

16.

Goh J, Sadler L, Rowan J . Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011; 28(9):1082-7. DOI: 10.1111/j.1464-5491.2011.03361.x. View

17.

Lowe L, Metzger B, Dyer A, Lowe J, McCance D, Lappin T . Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012; 35(3):574-80. PMC: 3322718. DOI: 10.2337/dc11-1687. View

18.

Rowan J, Hague W, Gao W, Battin M, Moore M . Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008; 358(19):2003-15. DOI: 10.1056/NEJMoa0707193. View

19.

Balsells M, Garcia-Patterson A, Sola I, Roque M, Gich I, Corcoy R . Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015; 350:h102. PMC: 4301599. DOI: 10.1136/bmj.h102. View

20.

Ali A, Shastry S, Nithiyananthan R, Ali A, Ganapathy R . Gestational diabetes-Predictors of response to treatment and obstetric outcome. Eur J Obstet Gynecol Reprod Biol. 2017; 220:57-60. DOI: 10.1016/j.ejogrb.2017.11.014. View